Lilly signs Stipple cancer pact, up to $5.9B
Eli Lilly has signed a multi-target oncology research and licensing partnership with Stipple Bio that could be worth up to $5.9 billion. Stipple will receive an undisclosed upfront payment and equity investment, with additional milestone payments and, according to some reports, tiered royalties; Lilly gets exclusive worldwide rights to develop and commercialize resulting products. The collaboration will use Stipple’s Pointillist Platform to identify tumor-specific cell-surface targets, with the aim of creating cancer therapies that are more effective and cause less damage to healthy tissue. The deal expands Lilly’s oncology pipeline as it seeks growth beyond its diabetes and obesity medicines.




